Literature DB >> 17331587

Use of a platform in an automated open-field to enhance assessment of anxiety-like behaviors in mice.

Vladimir M Pogorelov1, Thomas H Lanthorn, Katerina V Savelieva.   

Abstract

The present report describes a setup for simultaneously measuring anxiety-like behaviors and locomotor activity in mice. Animals are placed in a brightly lit, standard automated open-field (OF) in which a rectangular ceramic platform 8 cm high covers one quadrant of the floor. Mice preferred to stay under the platform, avoiding the area with bright illumination. Activities under and outside the platform were measured for 5 min. Chlordiazepoxide and buspirone dose-dependently increased time spent outside the platform (L-Time) and the light distance to total OF distance ratio (L:T-TD) in both genders without changing total OF distance. By contrast, amphetamine decreased L-Time and L:T-TD in males, thus displaying an anxiogenic effect. Imipramine was without selective effect on L-Time or L:T-TD, but decreased total OF distance at the highest dose indicative of a sedative effect. Drug effects were also evaluated in the OF without platform using conventional anxiety measures. Introduction of the platform into the OF apparatus strongly enhanced the sensitivity to anxiolytics. Comparison of strains differing in activity or anxiety levels showed that L-Time and L:T-TD can be used as measures of anxiety-like behavior independent of locomotor activity. Changes in motor activity are reflected in the total distance traveled under and outside the platform. Therefore, the platform test is fully automated, sensitive to both anxiolytic and anxiogenic effects of drugs and genetic phenotypes with little evidence of gender-specific responses, and can be easily utilized by most laboratories measuring behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17331587     DOI: 10.1016/j.jneumeth.2007.01.015

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  6 in total

1.  Assessing the efficacy of specific cerebellomodulatory drugs for use as therapy for spinocerebellar ataxia type 1.

Authors:  Nupur Nag; Volga Tarlac; Elsdon Storey
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

2.  Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice.

Authors:  Paolo Magnani; Anita Conforti; Elisabetta Zanolin; Marta Marzotto; Paolo Bellavite
Journal:  Psychopharmacology (Berl)       Date:  2010-04-20       Impact factor: 4.530

3.  Normalizing dopamine D2 receptor-mediated responses in D2 null mutant mice by virus-mediated receptor restoration: comparing D2L and D2S.

Authors:  K A Neve; C P Ford; D C Buck; D K Grandy; R L Neve; T J Phillips
Journal:  Neuroscience       Date:  2013-06-27       Impact factor: 3.590

4.  Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.

Authors:  David R Powell; Jason P Gay; Nathaniel Wilganowski; Deon Doree; Katerina V Savelieva; Thomas H Lanthorn; Robert Read; Peter Vogel; Gwenn M Hansen; Robert Brommage; Zhi-Ming Ding; Urvi Desai; Brian Zambrowicz
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-02       Impact factor: 5.555

5.  Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein.

Authors:  Eduard Bentea; Anke Van der Perren; Joeri Van Liefferinge; Anissa El Arfani; Giulia Albertini; Thomas Demuyser; Ellen Merckx; Yvette Michotte; Ilse Smolders; Veerle Baekelandt; Ann Massie
Journal:  Front Behav Neurosci       Date:  2015-03-31       Impact factor: 3.558

6.  Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation.

Authors:  Sergio Vegas-Suárez; Teresa Morera-Herreras; Catalina Requejo; José Vicente Lafuente; Rosario Moratalla; Cristina Miguélez; Luisa Ugedo
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.